New drug avoids treatment problem for hepatitis C patients

10/31/2006 | HealthDay News

Researchers say hepatitis C patients with cirrhosis and low platelet levels can take standard antiviral medications if they also use the new drug eltrombopag. Two common drugs, ribavirin and pegylated interferon, further reduce platelet levels in patients, but eltrombopag counters that effect.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA